Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age≥18 years as of the screening date;
• Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
• Prescribed Evolocumab at physician's discretion;
• Signed informed consent.
Locations
Other Locations
China
Beijing Tiantan Hospital
RECRUITING
Beijing
Contact Information
Primary
Jie Xu
xujie@ncrcnd.org.cn
59975672
Backup
Aichun Cheng
aichuncheng0822@163.com
13240768490
Time Frame
Start Date: 2025-11-03
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 4000
Treatments
Experimental: the Intelligent Lipid Management Decision-support System
Doctor's Side: Long-term lipid management support based on guidelines/consensus• Provides lipid management pathways based on guidelines/consensus to ensure clinical decisions align with the latest standards.• Combines individualized patient data to offer intelligent lipid management and medication suggestions.• Provides medical education support to enhance doctors' awareness of guidelines, consensus, and management strategies.Patient's Side: Personalized lipid risk assessment and regular reminders• Based on the lipid test reports uploaded by patients via photos, provides lipid test reports tailored to the patient's risk stratification.• Uses digital tools to regularly remind patients, optimizing follow-up adherence and medication compliance.
No_intervention: Usual Care
Usual Care
Related Therapeutic Areas
Sponsors
Leads: Beijing Tiantan Hospital